|View printer-friendly version|
|September 05, 2002 4:20 p.m.|
|Teva Announces Approval of Cefaclor ER Tablets|
Jerusalem, Israel, September 5, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has approved the Company's ANDA for Cefaclor Extended Release Tablets USP, 375 mg and 500 mg. This is the first generic approval for the 375 mg strength. Shipment of this product is expected to begin immediately.